We performed data mining of the NCI-60 Human Tumor Cell Lines Screen (Developmental Therapeutics Program) in order to find compounds that preferentially suppress growth of TP53 nonsense mutant tumor cells as compared to tumor cells carrying other TP53 mutations or wild-type (WT) TP53. We extracted mean 50% growth-inhibitory concentrations (GI50) for 47 000 compounds in colon and renal cancer cell lines (Fig. S1A). The gene discussed is TP53; the disease is renal carcinoma.